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Abstract 
Purpose: To assess the effects of oral glutamate intake on acute motor effects and chronic intake of 
ethanol in rodents. 
Methods: The acute effects of ethanol on motor function were studied in ICR mice by giving 2 or 6 g/kg 
of ethanol 2 h after distilled water or 2.5 g/kg glutamate per os. Thirty minutes after ethanol treatment, 
behavioral assays, including rotarod tests and foot print analysis were monitored. In chronic ethanol 
treatment, male Wistar rats were trained to consume ethanol-sucrose solution during a 2-h period daily, 
starting with 2 % ethanol/10 % sucrose and gradually increasing to 10 % ethanol/5 % sucrose solution 
over 56 days. After training session, the drug treatment phase was done for 10 days. The animals were 
force-fed 50 mg/kg/day topiramate or 2.5 g/kg/day glutamate 2 h before ethanol treatment sessions. 
Each day, ethanol intake, water intake, food intake and body weight were recorded.                           
Results: Mice that received 2 or 6 g/kg of ethanol orally, showed a significant reduction in time on the 
rod in the rotarod test and a significant increase in both forelimb and hindlimb stride lengths when 
compared to control. Oral treatment with 2.5 g/kg of glutamate reversed the acute motor effects of 
ethanol. In chronic ethanol treatment, the intake of 10 % ethanol/5 % sucrose, accessible for 2 h, was 
significantly decreased in rats treated with either topiramate or glutamate.  
Conclusion: These results provide evidence that oral glutamate administration help to reduce the acute 
motor effects of ethanol in mice and ethanol intake in the chronic ethanol drinking rats.  
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Glutamate, the principal excitatory amino acid 
neurotransmitter present in the mammalian brain, 
is one of the neurotransmitters responsible for 
neuronal effects of ethanol in both acute and 
chronic alcohol consumption. In acute alcohol 
consumption, all glutamate receptors, including 
N-methyl-D-aspartate (NMDA) and L-alpha-
amino-3-hydroxy-5-methyl-isoxazole-4-propionic 
acid ionotropic (AMPA) receptors are inhibited 
[1]. Together with increased inhibitory 
neurotransmission through gamma-aminobutyric 
acid (GABA), acute alcohol exposure leads to a 
sedated state and impaired motor coordination in 
drinkers [1,2]. On the other hand, chronic use of 
alcohol seems to upregulate  NMDA receptor 
expression in the brain and leads to alcohol 
dependence and relapse-like alcohol drinking 
[1,2]. Glutamate also plays an important role in 
the reward system of alcohol addiction [3,4,5]. 
Increased extracellular glutamate levels were 
observed in the reward system during ethanol 
withdrawal [6]. Currently, several studies have 
focused on the investigation of glutamatergic 
agents in maintaining glutamate homeostasis, 
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modifying alcohol’s effects, and reducing alcohol 
intake [7,8]. Acamprosate, one of the approved 
treatments for alcoholism, is proposed to exert at 
least part of its effsct by altering glutamatergic 
function [9,10]. Topiramate, an anticonvulsant, 
that inhibits glutamate release and blocks 
AMPA/kainate receptors, can also be used in the 
treatment of alcohol dependence [11]. 
 
Glutamate is found in abundant amounts in many 
natural and prepared foods as a food flavoring 
agent for the umami taste. Recently, it was 
shown that monosodium glutamate at 2.5 or 4 
g/kg per os could markedly elevate the glutamate 
level in the brain and other organs in mice and 
reached peak values at 90 - 120 min [12]. Thus, 
when drinking alcohol with food as a source of 
glutamate, interactions between ethanol and 
glutamate might occur. This study was aimed to 
investigate the effects of oral administration of 
glutamate on the acute effects of ethanol on 





Experimental animals  
 
In this study, male outbred Mlac:ICR mice, 6-8 
wks old, weighing 25–35 g, and male outbred 
Wistar rats, 6-8 wks old, weighing 250–350 g, 
were purchased from the National Laboratory 
Animal Center, Mahidol University, Thailand. The 
animals had free access to a commercial diet 
(CP, Thailand) and water, and were housed in a 
room with a 12-h light: 12-h dark cycle under 
controlled temperature and humidity. All animal 
experiments were strictly in accordance with 
international ethical guidelines [13] and Ethics of 
Animal Experimentation of National Research 
Council of Thailand concerning the Care and Use 
of Laboratory Animals. The experimental 
protocols also received the approval of Animal 
Ethics Committee of Khon Kaen University 
(approval no. 0514.1.12.2/78).  
 
Chemicals and reagents 
 
Ethanol (BDH Prolabo Chemicals, EC), sucrose 
(Ajax Fine Chem Pty Ltd, New Zealand), 
topiramate (Topamax®, Janssen 
Pharmaceuticals, Inc. Toronto, Canada) and L-
glutamic acid (Sigma-Aldrich, USA) were used in 
this study. The chemicals were dissolved in 
distilled water on the day of the experiment and 
given to the animals in a dose of 0.05 ml/10 g 
body weight. Doses of ethanol used were 
expressed as g/kg. 
 
Acute ethanol treatment 
 
Each of the mice were force fed two times 2 h 
apart. First, distilled water or 2.5 g/kg glutamate 
[12] was administered followed by distilled water 
or ethanol (2 or 6 g/kg) [14]. Thirty minutes after 
the second treatment, the rotarod tests and foot 




The rotarod test was done to assess motor 
coordination and balance in mice. The AccuRotor 
Rotarod (Accuscan Instruments, Columbus, OH) 
was used for fixed-speed rota-rod (FSRR) tests. 
Mice were placed with the forepaws on bars 
(diameter 2.5 cm) which were turning at 12 rpm 
and the time that the animal remained on the rod 
was recorded [14]. The maximum observed time 
was set at 60 s. 
 
Foot print analysis 
 
Foot print analysis was used to assess ataxia 
and gait abnormalities in mice as described 
earlier [15]. Animals were made to walk along a 
60 cm long, 7 cm wide runner with 10 cm walls 
by lighting a lamp at the start and placing a dark 
box at the end. The runner was lined with white 
paper, and the fore and hind paws of the animals 
were dipped in red and blue nontoxic colors to 
record the footprints. Six middle steps of a series 
of steps were analyzed and the distances 
between two forelimb and two hindlimb pawprints 
were measured as forelimb stride length (FSL) 
and hindlimb stride length (HSL), respectively. 
 
Assessment of chronic ethanol consumption 
in rats 
 
In this chronic study, male Wistar rats were 
treated as described earlier [16] and topiramate, 
an antiepileptic agent that reduces ethanol 
consumption [11] was used as a positive control. 
Animals were individually housed and received 
ad libitum access to standard rodent chow and 
water. The experiments were performed during 
the light cycle. In the training phase, rats were 
given free access to ethanol in sucrose solutions 
during two-hour sessions at 10:00-12:00 am of 
each day for 56 days. Ethanol–sucrose solutions 
were presented in 25 mL graduated plastic tubes 
with rubber stoppers and metal sipper tubes 
were inserted through the cage. The 
concentration of ethanol in these solutions was 
systematically increased, while the concentration 
of sucrose was decreased over a 56-day period. 
The ethanol-sucrose solution given to the 
animals were 2 % ethanol/10 % sucrose solution 
on days 1-11, 5 % ethanol–5 % sucrose solution 
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on days 12 - 24, 8 % ethanol/5 % sucrose 
solution on days 25 - 38 and 10 % ethanol/5 % 
sucrose solution on days 39 - 56 which continued 
for another 10 days for the treatment phase. The 
10th day drug treatment phase began after 
animals had completed 8 weeks (56 days) of 
training on drinking. Animals were randomly 
assigned to control (distilled water), topiramate at 
50 mg/kg/day and glutamate at 2.5 g/kg/day 
treatment groups with 6 animals in each group. 
On each day of the drug treatment phase, 2 h 
before the ethanol session, animals received 
intragastrically distilled water, 50 mg/kg 
topiramate or 2.5 g/kg glutamate, once daily. 
After that, a 2-h session of free access to a 10 % 
ethanol–5 % sucrose solution was initiated. On 
each day, the amount of ethanol intake (g/kg) in 
the two-hour session, water intake (ml/day) and 
food intake (g/day) were recorded. Animal body 
weights were recorded daily during the whole 





The data are presented as means ± standard 
error of means (SEM). For the acute effects of 
ethanol on motor functions, one-way analysis of 
variance (ANOVA) followed by Tukey post-hoc 
test) and Student t-tests were used. Results were 
considered significant at p < 0.05. In the 
assessment of chronic ethanol consumption in 
rats, two-way ANOVA with groups and times as 





Effect of glutamate on acute ethanol 
treatment 
 
In the rotarod test, the control animals on water-
only showed normal coordination and could stay 
on the rod for over 60 sec. Ethanol, at either 2 or 
6 g/kg, significantly (p < 0.001) decreased the 
time on rod when compared to the control 
(Figure 1). Mice that received 2.5 g/kg glutamate 
had normal coordination and could stay on rod 
for over 60 sec. Time on rods of mice that 
received glutamate with either 2 or 6 g/kg of 
ethanol were comparable to the control which 
suggested that glutamate could completely 
reverse the effects of ethanol. 
 
Foot print analysis showed that the control 
animals used only the front parts of the paws to 
walk on and a narrow-based stance with close 
proximity forelimb and hindlimb footprints with 
5.71 ± 0.48 and 5.30 ± 0.49 cm of forelimb and 
hindlimb stride lengths. The stepping patterns of 
animals that received either doses of ethanol 
were different from the control animals. Animals 
treated with ethanol, at either 2 or 6 g/kg, walked 
on their whole paw with a significant increase in 
FSL (p = 0.037, 0.043) and HSL (p = 0.010, 
0.050) when compared to the control (Figure 2). 
Mice that received 2.5 g/kg glutamate could 
reverse the effects of 2 g/kg, but not 6 g/kg, of 
ethanol on FSL and HSL to the control length. 
 
 
Figure 1: Effect of glutamate on ethanol-induced changes in coordination in the rotarod test. Ethanol, at either 2 
or 6 g/kg, significantly (p<0.001) reduced the time on the bar. Glutamate (2.5 g/kg) reversed the effects of ethanol 
on coordination. Significant differences, when compared to the control, are denoted by * 
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Figure 2: Effects of glutamate on ethanol-induced changes in FSL and HSL. Ethanol 2 or 6g/kg could 
significantly increase both FSL and HSL. Glutamate (2.5 g/kg) reversed the effects of 2 g/kg ethanol on FSL and 
HSL to normal levels.  *Significantly different, compared to the control 
 
Table 1: Effect of glutamate and topiramate on ethanol intake in rats 
 
Day 
Control TPM (50mg/kg/day) Glutamate (2.5g/kg/day) 
Ethanol Intake 
(g/kg/2 h) 
(mean + SEM) 
Ethanol Intake 
(g/kg/2 h) 






(mean + SEM) 
 
P-value 
1 1.411 + 0.048 1.066 + 0.078* 0.004 1.344 + 0.106 1.000 
2 1.819 +0.110 1.290 +  0.104* 0.026 1.331 + 0.102* 0.044 
3 1.607 +0.159 1.103+0.133* 0.035 1.382 +  0.175 0.146 
4 1.719 + 0.163  1.042 + 0.0659* 0.018 1.252 + 0.128* 0.048 
5 1.604 + 0.133  0.781 + 0.0613*  0.002 1.008 + 0.107*  0.028 
6 1.604 + 0.178  0.910 + 0.107* 0.012 1.025 + 0.131* 0.042 
7 1.584 + 0.137  0.939 + 0.133* 0.016 1.028 + 0.113* 0.041 
8 1.786 + 0.180  0.858 + 0.109* 0.003 1.376 + 0.167  0.126 
9 1.768 + 0.292  0.680 + 0.120* 0.008 1.010 + 0.113*  0.036 
10 1.699 + 0.190  0.867 + 0.122* 0.002 0.973 + 0.112* 0.007 
All values are expressed as mean ± SEM. Significant differences are denoted by * when compared to the control 
group of the same day 
 
Effect of glutamate on chronic ethanol 
consumption 
 
At the end of the training phase, the mean daily 
intake of ethanol in g/kg for each treatment group 
for the baseline phase, was of 1.529 g/kg/2-h 
session (± 0.088 SEM). During the 10 days of the 
treatment phase, the control animals showed no 
change in the amount of ethanol intake. A 
significant reduction of ethanol intake that was 
seen in topiramate-treated group, when 
compared to the control, can be seen from day 1 
to day 10 (Table 1). Glutamate treatment, at 2.5 
mg/kg/day, also significantly reduced the amount 
of ethanol intake from day 2 to day 10 and the 
effects were comparable to topiramate at 50 
mg/kg/day. A two-way repeated measures 
ANOVA showed a significant effect of treatment 
[F(3, 239) = 16.618, p < 0.001], without any 
significance in treatment x day interactions (p = 
0.869). 
 
Significant reduction of ethanol intake (g/kg/two-
hour session) can be seen in rats treated with 
topiramate (50 mg/kg/day) or glutamate (2.5 
g/kg/day) from day 1 or day 2 of the treatment 
phase and was still prominent at the end of the 
experiment.  
 
No significant differences of the mean volume of 
water, food intake or change of body weight 
could be seen in all treatment groups when 




Recently, it has been shown that monosodium 
glutamate (MSG), the primary component of 
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umami taste, can be used as a substitute to 
initiate ethanol drinking in both C57BL/6J and 
DBA/2J mice [17]. Interestingly, this study is the 
first to show that intragastric administration of 
glutamate could reduce both the acute effects of 
ethanol on motor functions and chronic ethanol 
intake.  
 
Generally, ethanol modulates synaptic efficacy in 
many brain areas, including the cerebellum and 
cortical regions [18,19] and causes motor 
impairment from the inhibition of ionotropic 
glutamate receptors and enhancing the inhibitory 
action of GABA [20,21]. It is noted that glutamate 
could be detected in the brain with peak 
concentrations at approximately 2 h after oral 
administration of 2.5 g/kg glutamate [17]. In the 
present study, oral administration of glutamate, 2 
h before ethanol, might have increased the 
glutamate levels in the brain, activated glutamate 
receptors and helped reduce the acute effects of 
ethanol on motor functions.  
 
In the chronic ethanol consumption model, 
topiramate treatment clearly reduced the ethanol 
intake of the rats. It has been shown previously 
that topiramate, by facilitation of inhibitory GABA 
effects and antagonism of AMPA/kainate 
glutamate receptors can decrease ethanol 
reinforcement and the propensity to drink [22,23]. 
Recently, glutamate was able to induce more 
ethanol drinking in C57BL6/J and DBA/2J mice 
and the authors suggested that the umami effect 
of glutamate is responsible for the effect [17]. In 
the present experiment, glutamate administered 
by an intragastric tube, bypassed the umami 
taste, reduced ethanol intake in rats with a 
history of chronic alcohol consumption. It is 
interesting to note that changes in the balance 
between synaptic and extrasynaptic glutamate 
levels in the brain in turn influence signaling 
through pre- and post-synaptic glutamate 
receptors, and thus affect synaptic plasticity and 
circuit-level activity [24].  
 
In chronic exposure to cocaine, a decrease in 
extrasynaptic glutamate concentrations in the 
nucleus accumben (NAc) and a decreased tone 
of presynaptic inhibitory mGluR2/3 glutamate 
receptors was observed [24]. MGluR2/3 
glutamate receptors are inhibitory to 
glutamatergic neurotransmission; the decreased 
tone of these receptors leads in turn to enhanced 
glutamate release in the prefrontal cortex-NAc 
projection and activates drug-seeking behavior 
[25]. Giving glutamate orally might increase 
extrasynaptic glutamate level in the brain [17,26] 
and reduce ethanol-seeking behavior.  
 
The results from this study suggest that, 
glutamate, as one of the common ingredients 
found in all kinds of foods, might exert a very 
interesting interaction with ethanol in either its 




These results provide evidence that oral 
glutamate administration reduces acute motor 
effects of ethanol and ethanol intake in the 
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